Last edition
News about
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
Sunrise Air Receives US FDA Clearance, Expanding Access to At-Home Sleep Apnoea Diagnosis
Sunrise Air, Sunrise Group’s FDA-cleared next-generation home sleep testing device, combines AI-powered analysis and advanced sensor technology to deliver accessible, clinically robust sleep apnoea diagnosis from home.
NunaBio Raises Euro 6.5 Million to Scale Next-Generation DNA Manufacturing Platform
NunaBio’s latest funding to accelerate DNA micro-foundry development, expand manufacturing capabilities and strengthen infrastructure for synthetic biology, therapeutics, and research applications.
1st ICMR Clinical Trial Meet 2026 Showcases India's Growing Role in Integrative Medicine Research
The Indian Council of Medical Research (ICMR) Annual Clinical Trial Meet 2026 highlighted India’s growing leadership in integrative medicine research, alongside new initiatives to strengthen phase 1 clinical trials and streamline ethics review for multicenter studies.
Fujifilm Cellular Dynamics Opens New iPSC Manufacturing Facility in Madison
Fujifilm Cellular Dynamics opens a new iPSC manufacturing facility and headquarters in Madison as part of Fujifilm’s USD 200 million investment to expand cell therapy and stem cell manufacturing capabilities in the US.
Hansa Biopharma Signs IDEFIRIX Licensing Deal with SERB Pharmaceuticals for Europe and MENA
Hansa Biopharma signs a €115 million licensing agreement with SERB Pharmaceuticals for commercialisation of IDEFIRIX across Europe and MENA, strengthening its financial position ahead of a potential US launch.
MaaT Pharma Updates Marketing Authorisation Application for MaaT013 in Acute GvHD Treatment
MaaT Pharma reports a negative trend opinion from the EMA’s CHMP for the marketing authorisation application of MaaT013 in acute Graft-Versus-Host Disease (aGVHD), with plans to seek re-examination following the formal June CHMP vote.
Samsung Bioepis Launches First Biosimilar Product in Japan with Ustekinumab Therapy
Samsung Bioepis launches its ustekinumab biosimilar in Japan through a partnership with Nipro Corporation, expanding access to affordable treatments for chronic autoimmune diseases.
US FDA Grants Priority Review to HYRNUO for HER2-Mutated NSCLC
The US FDA has granted Priority Review (PR) to HYRNUO (sevabertinib) as a first-line treatment for HER2-mutated Non-Small Cell Lung Cancer (NSCLC), based on phase 1/2 SOHO-01 trial data.
Dr. Reddy's Launches Oral Semaglutide Biosimilar Obeda Tablets in India
Dr. Reddy's launches Obeda oral semaglutide tablets in India, strengthening its GLP-1 portfolio after recent generic semaglutide injection launches in India and Canada for diabetes and obesity care.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy